No Data
No Data
Minsheng Health (301507.SZ): Currently, it does not involve the production of APIs, nor does it involve the production of synthetic biological APIs
Gelonghui, May 8 | Minsheng Health (301507.SZ) said on the investor interactive platform that the company focuses on the field of vitamin and mineral supplements and is a high-tech enterprise integrating R&D, production and sales of vitamin and mineral non-prescription drugs and health foods. Currently, the products sold by the company are mainly vitamin and mineral supplement series products. Please refer to the instructions for each product for specific product functions, product efficacy ingredients, and product application groups. The company is currently not involved in the production of APIs, nor is it involved in the production of synthetic biological APIs.
Minsheng Health (301507.SZ): Net profit of 58.7723 million yuan in the first quarter increased by 6.51% year-on-year
On April 23, Ge Longhui | Minsheng Health (301507.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 235 million yuan, up 5.78% year on year; net profit attributable to shareholders of listed companies was 588.723 million yuan, up 6.51% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 57.0676 million yuan, up 3.95% year on year; basic earnings per share were 0.1,700 yuan.
Minsheng Health (301507.SZ): Focus on the field of vitamin and mineral supplements
Gelonghui, April 17 | Minsheng Health (301507.SZ) said on the investor interactive platform that the company focuses on the field of vitamin and mineral supplements, and currently sells mainly vitamin and mineral supplement series products.
Hangzhou Minsheng Healthcare Co., Ltd.'s (SZSE:301507) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Hangzhou Minsheng Healthcare (SZSE:301507) has had a rough three months with its share price down 28%. However, stock prices are usually driven by a company's financials over the long term, which in
Minsheng Health (301507.SZ): The ban on 4.593 million restricted shares will be lifted on March 5
Gelonghui, February 28, 丨 Minsheng Health (301507.SZ) announced an indicative announcement on the listing and circulation of restricted shares for the initial public offering. The total number of shareholders whose sales restrictions have been lifted is 6,951, and the number of shares that have been lifted is 4,593 million shares, accounting for 1.29% of the company's total share capital. The sales restriction period is 6 months from the date of the company's initial public offering and listing. The stock listing and circulation date for which sales restrictions have been lifted is March 5, 2024 (Tuesday).
Minsheng Health (301507.SZ): 2023 net profit pre-increased 6.35%-11.42%
Gelonghui, January 15, 丨 Minsheng Health (301,507.SZ) announced its 2023 annual results forecast, with operating income of 58,000,000 yuan to 60,000,000 yuan, an increase of 6.01% to 9.67% over the same period of the previous year; net profit attributable to shareholders of listed companies was 84.0 million yuan - 88.0 million yuan, an increase of 6.35% to 11.42% over the same period of the previous year; net profit profit after deducting non-recurring profit and loss of 74.0 million yuan to 80.2 million yuan over the same period of the previous year 5.28% —16.66
No Data